Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).

No abstract is available for this paper.

• Publication year

  2013

• Venue

  MMWR Recommendations and Reports

• Publication date

  2013-06-14

• Fields of study

  Medicine

• Identifiers
  PMID 23760231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidemiology of a Mumps Outbreak in a Highly Vaccinated Island Population and Use of a Third Dose of Measles–Mumps–Rubella Vaccine for Outbreak Control—Guam 2009 to 2010

  2013influential reference
• Mumps outbreak in Orthodox Jewish communities in the United States.

  2012influential reference
• Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008.

  2012cited by this paper
• Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak.

  2012cited by this paper
• Fatal Measles without Rash in Immunocompetent Adult, France

  2012cited by this paper
• Documentation and verification of measles, rubella and congenital rubella syndrome elimination in the region of the Americas : United States national report, March 28, 2012

  2012cited by this paper
• Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.

  2012cited by this paper
• Impact of a Third Dose of Measles-Mumps-Rubella Vaccine on a Mumps Outbreak

  2012influential reference
• Measles-Containing Vaccines and Febrile Seizures in Children Age 4 to 6 Years

  2012cited by this paper
• Mumps outbreak on a university campus--California, 2011.

  2012cited by this paper
• Characterization of measles virus strains causing SSPE: A study of 11 cases

  2011cited by this paper
• Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity.

  2011cited by this paper
• Guidelines for the documentation and verification of measles, rubella, and congenital rubella syndrome elimination in the region of the Americas.

  2011cited by this paper
• Evidence used to support the achievement and maintenance of elimination of rubella and congenital rubella syndrome in the United States.

  2011cited by this paper
• An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada

  2011cited by this paper
• Field effectiveness of live attenuated measles-containing vaccines: a review of published literature.

  2011influential reference
• IMMUNIZATION OF HEALTH-CARE PERSONNEL: RECOMMENDATIONS OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)

  2011cited by this paper
• Progress toward control of rubella and prevention of congenital rubella syndrome--worldwide, 2009.

  2011cited by this paper
• Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

  2010cited by this paper
• Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy.

  2010cited by this paper
• Measles in the United States during the postelimination era.

  2010cited by this paper
• Guidance for isolation precautions for mumps in the United States: a review of the scientific basis for policy change.

  2010cited by this paper
• Mumps vaccine effectiveness in highly immunized populations.

  2010cited by this paper
• HEALTH and HUMAN SERVICES

  2010cited by this paper
• Early waning of maternal measles antibodies in era of measles elimination: longitudinal study

  2010cited by this paper
• Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures

  2010cited by this paper
• The effectiveness of prophylaxis for measles contacts in NSW.

  2009cited by this paper
• Evaluation of cellular immunity to mumps in vaccinated individuals with or without circulating antibodies up to 16 years after their last vaccination.

  2009cited by this paper
• Mumps resurgences in the United States: A historical perspective on unexpected elements.

  2009cited by this paper
• Immunization Policy Development in the United States: The Role of the Advisory Committee on Immunization Practices

  2009cited by this paper
• The rationale for the use of measles post-exposure prophylaxis in pregnant women: A review

  2009cited by this paper
• Estimates of measles case fatality ratios: a comprehensive review of community-based studies.

  2009cited by this paper
• Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine.

  2009cited by this paper
• Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children

  2009cited by this paper
• Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine.

  2009cited by this paper
• Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting.

  2009cited by this paper
• Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and Revaccination

  2009cited by this paper
• Effectiveness of Jeryl Lynn-containing vaccine in Spanish children.

  2009cited by this paper
• Rubella Outbreak in the Netherlands, 2004–2005: High Burden of Congenital Infection and Spread to Canada

  2009cited by this paper
• Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up.

  2008cited by this paper
• Is MMR immunisation safe in chronic Idiopathic thrombocytopenic purpura?

  2008cited by this paper
• Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi.

  2008cited by this paper
• Long-term persistence of mumps antibody after receipt of 2 measles-mumps-rubella (MMR) vaccinations and antibody response after a third MMR vaccination among a university population.

  2008cited by this paper
• Risk of Immune Thrombocytopenic Purpura After Measles-Mumps-Rubella Immunization in Children

  2008cited by this paper
• Recent resurgence of mumps in the United States.

  2008influential reference
• Severity of measles among patients with incidental postexposure vaccination.

  2008cited by this paper
• Mumps vaccine performance among university students during a mumps outbreak.

  2008cited by this paper
• Immune responses to mumps vaccine in adults who were vaccinated in childhood.

  2008cited by this paper
• Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students--Iowa, 2006.

  2008cited by this paper
• Vaccine Effectiveness Estimates, 2004–2005 Mumps Outbreak, England

  2007cited by this paper
• HIV‐1‐infected children on HAART: Immunologic features of three different levels of viral suppression

  2007cited by this paper
• Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination.

  2007cited by this paper
• Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.

  2007cited by this paper
• Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.

  2007cited by this paper
• Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.

  2007cited by this paper
• Fetal Risk Associated With Rubella Vaccination During Pregnancy

  2007cited by this paper
• Detection and characterization of measles virus strains in cases of subacute sclerosing panencephalitis in Croatia.

  2007cited by this paper
• Seroprevalence of measles antibody in the US population, 1999-2004.

  2007cited by this paper
• Review of the effect of measles vaccination on the epidemiology of SSPE.

  2007influential reference
• Humoral Immune Response after Primary Rubella Virus Infection and after Vaccination

  2007cited by this paper
• Idiopathic thrombocytopenic purpura and the second dose of MMR

  2007cited by this paper
• Effectiveness of Previous Mumps Vaccination During a Summer Camp Outbreak

  2007cited by this paper
• Evaluation of Potentially Common Adverse Events Associated With the First and Second Doses of Measles-Mumps-Rubella Vaccine

  2006cited by this paper
• Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy–Treated Children With HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral Infection

  2006cited by this paper
• Waning antibodies in measles and rubella vaccinees--a longitudinal study.

  2006cited by this paper
• The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement.

  2006cited by this paper
• The epidemiological profile of rubella and congenital rubella syndrome in the United States, 1998-2004: the evidence for absence of endemic transmission.

  2006cited by this paper
• Inadvertent rubella vaccination of pregnant women: evaluation of possible transplacental infection with rubella vaccine.

  2006cited by this paper
• Prevalence of protective antibody against measles in HIV‐infected children with immune recovery after highly active antiretroviral therapy

  2006cited by this paper
• Measles-virus-neutralizing antibodies in intravenous immunoglobulins.

  2006cited by this paper
• Seroepidemiological profile of pregnant women after inadvertent rubella vaccination in the state of Rio de Janeiro, Brazil, 2001-2002.

  2006cited by this paper
• A Limited Measles Outbreak in a Highly Vaccinated US Boarding School

  2005cited by this paper
• Congenital rubella syndrome despite maternal antibodies

  2005cited by this paper
• An outbreak of mumps in Sweden, February-April 2004.

  2005cited by this paper
• Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized.

  2005cited by this paper
• [Frequency of spontaneous abortion and premature birth after acute mumps infection in pregnancy].

  2005cited by this paper
• Open Randomized Trial Comparing the Immunogenicity and Safety of a New Measles-Mumps-Rubella Vaccine and a Licensed Vaccine in 12- to 24-Month-Old Children

  2005cited by this paper
• The effectiveness of the mumps component of the MMR vaccine: a case control study.

  2005cited by this paper
• Incremental effectiveness of 2 doses of measles-containing vaccine compared with 1 dose among high school students during an outbreak.

  2004cited by this paper
• RISK OF ANAPHYLAXIS AFTER VACCINATION OF CHILDREN AND ADOLESCENTS

  2004cited by this paper
• Evolution of measles elimination strategies in the United States.

  2004cited by this paper
• Summary and conclusions: measles elimination meeting, 16-17 March 2000.

  2004cited by this paper
• MMR immunisation after contact with measles virus.

  2004cited by this paper
• The clinical significance of measles: a review.

  2004cited by this paper
• MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.

  2004cited by this paper
• Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.

  2004cited by this paper
• Symptomatic rubella re‐infection in pregnancy with no evidence of fetal infection

  2004cited by this paper
• Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States.

  2004cited by this paper
• Pregnancy outcome following rubella vaccination: A prospective controlled study

  2004cited by this paper
• Rubella Immunization in Human Immunodeficiency Virus Type 1-Infected Children: Cause for Concern in Vaccination Strategies

  2004cited by this paper
• Acute measles mortality in the United States, 1987-2002.

  2004cited by this paper
• The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990–2002

  2004cited by this paper
• An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.

  2004cited by this paper
• Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy.

  2003cited by this paper
• Risk of anaphylaxis after vaccination of children and adolescents.

  2003cited by this paper
• Immunization of children at risk of infection with human immunodeficiency virus.

  2003cited by this paper
• Absence of transmission of the d9 measles virus--Region of the Americas, November 2002-March 2003.

  2003cited by this paper
• An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines.

  2002cited by this paper
• Molecular analysis of measles virus genome derived from SSPE and acute measles patients in Papua, New Guinea

  2002cited by this paper
• Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

  2002cited by this paper

• Social Determinants and Outbreak Dynamics of the 2025 Measles Epidemic in Mexico: A Nationwide Analysis of Linked Surveillance Data.

  2026cites this paper
• Measles: An Updated Literature Review of the Host Response, Pathogenesis, Complications, Prevention Measures, and Recent Outbreaks.

  2026cites this paper
• A coupled disease-misinformation model of measles transmission in the Canadian context

  2026cites this paper
• Clinical progress note: Measles.

  2026cites this paper
• Cutaneous Manifestations, Gestational Timing, and Fetal Effects of Infectious Dermatoses in Pregnancy: A Narrative Review

  2026cites this paper
• Vaccination Following Leukemia Treatment: Viral Vaccine Responses in Survivors of Acute Lymphoblastic Leukemia

  2025cites this paper
• Evaluating the impact of different MMR vaccination strategies on mumps incidence in Shapingba, China:An interrupted time series analysis.

  2025cites this paper
• Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine.

  2025cites this paper
• Uncovering the features of Measles-targeting human antibodies elicited by the MMR vaccine

  2025cites this paper
• Vaccinating patients with autoimmune diseases.

  2025cites this paper
• Measles.

  2025cites this paper
• Impact of 10-year measles, mumps and rubella booster vaccination program among healthcare personnel: a cross-sectional study.

  2025cites this paper
• Knowledge, Attitude and Practices of Rubella Vaccination Among Medical Students

  2025cites this paper
• Increasing the Rates of Postpartum Measles, Rubella, and Varicella Vaccination in Nonimmune Mothers: An Electronic Medical Record-Based Quality Improvement Intervention

  2025cites this paper
• MMR Vaccination Coverage and Epidemiological Patterns in Al-Baha, Saudi Arabia, 2020–2024: Analysis of Suspected and Laboratory-Confirmed Cases

  2025cites this paper
• Post-exposure prophylaxis for the prevention of measles: A systematic review.

  2025cites this paper
• Pediatric Vaccine-Induced Antibody Thresholds: Rethinking Pre-Immunosuppression Serologic Testing and Revaccination Implications.

  2025cites this paper
• Non-colorectal Cancer Screening and Vaccinations in Patients with Inflammatory Bowel Disease: Expert Review.

  2025cites this paper
• Differences in measles antibody titers among IVIGs and hyperimmune globulins

  2025cites this paper
• Measles - Resurgence of an Old Foe.

  2025cites this paper
• Science for vaccine policy: Independent review of the September 2025 ACIP processes, deliberations and votes.

  2025cites this paper
• Nurses' Perspectives on Caring for Critically Ill Children During a Measles Outbreak: A Case Report.

  2025cites this paper
• Navigating Measles Treatment in 2025: A Review on Vaccines, Medications, and Supplements

  2025influential citation
• MMRV vaccine safety: A comprehensive analysis of adverse events recorded among pediatric populations

  2025cites this paper
• What's Old Is New Again: Measles.

  2025cites this paper
• Vaccination des patients adultes porteurs d’une maladie rénale chronique

  2025cites this paper
• Evaluation and optimization of mumps-containing vaccination strategies: a study based on an individual-based stochastic model

  2025cites this paper
• A Comparison of Vaccination Policies and Immunity Assessment for Measles Control: Insights from the United States and Japan

  2025cites this paper
• Epidemiology, clinical overview, and potential risk of a new pandemic of measles virus

  2025cites this paper
• Incremental effectiveness of the second dose of mumps-containing vaccine among children 9 months to 6 years in Hefei: A matched case-control study

  2025cites this paper
• Sudden Unilateral Profound Sensorineural Hearing Loss Due To Mumps

  2025cites this paper
• Early MMR vaccination during measles outbreaks: Reconsidering routine timing.

  2025cites this paper
• Vaccination Outcomes and Recommendations Among Older Adults in a Gastroenterology and Hepatology Practice.

  2025cites this paper
• Patterns of Decline in Measles, Mumps, and Rubella Neutralizing Antibodies and Protection Levels Through 10 Years After a Second and Third Dose of MMR Vaccine.

  2025cites this paper
• Verification of Immunity to Measles in Adults

  2025cites this paper
• Seroprevalence and Incidence of Measles, Mumps, and Rubella in Adult Solid Organ Transplant Recipients in the United States: A Large Database Analysis.

  2025cites this paper
• The Continued Risk of Measles Outbreaks in the United States Resulting From Suboptimal Vaccination Coverage.

  2025cites this paper
• ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease.

  2025cites this paper
• Measles Outbreaks 2025 and Beyond: Implications for Immunosuppressed Patients Managed by Gastroenterologists and Hepatologists.

  2025cites this paper
• Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations

  2025cites this paper
• Infection prevention in the immunocompromised traveler due to conditions other than transplantation: a review

  2025cites this paper
• Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.

  2025cites this paper
• Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US.

  2025cites this paper
• Measles Update — United States, January 1–April 17, 2025

  2025influential citation
• Measles and Solid Organ Transplantation: Diagnosis, Treatment, and Prevention

  2025influential citation
• Anti-vaccine antibodies against measles, rubella, parotitis and hepatitis B in children with inflammatory bowel disease and healthy controls

  2025cites this paper
• Low incidence of Varicella in Pediatric Patients with Inflammatory Bowel Disease.

  2025cites this paper
• Deciding Whether to Accept an Unvaccinated Child into a Pediatric Practice.

  2025cites this paper
• Descriptive Analysis of Measles Transmission Among Travelers During Domestic and Inbound US International Air Travel, 2018‐2019

  2025cites this paper
• Who Will Protect the Children?

  2025cites this paper
• Vaccination Update and Specific Concerns for RA

  2025cites this paper
• Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America.

  2024cites this paper
• Incomplete Immunity for Varicella and Measles in Pediatric Organ Transplant Candidates. Real World Experience From an Infectious Diseases Pre‐Transplantation Clinic

  2024cites this paper
• Modeling the population-level impact of a third dose of MMR vaccine on a mumps outbreak at the University of Iowa

  2024cites this paper
• The Effects of Vaccination Status and Age on Clinical Characteristics and Severity of Measles Cases in the United States in the Post-Elimination Era, 2001-2022.

  2024cites this paper
• Protective antibody concentrations in primary immunodeficiency following infusion with 5% or 10% intravenous immunoglobulin.

  2024cites this paper
• A conceptual health state diagram for modelling the transmission of a (re)emerging infectious respiratory disease in a human population

  2024cites this paper
• Molecular characterization of Mumps virus genotype C detected from Dibrugarh district of Assam, India

  2024cites this paper
• The Health and Economic Benefits of United States Investments in Measles and Rubella Control and Elimination

  2024cites this paper
• Live Typhoid and Yellow Fever Vaccines Administered to a Patient With Ulcerative Colitis on Vedolizumab

  2024cites this paper
• Appropriateness of Immunoglobulin M testing for Measles, Mumps, and Rubella.

  2024cites this paper
• A Cross-Sectional Study of Measles-Specific Antibody Levels in Australian Blood Donors—Implications for Measles Post-Elimination Countries

  2024cites this paper
• Postexposure prophylaxis after receipt of MMR vaccine prior to emergent heart transplant

  2024cites this paper
• Unwelcome return: analyzing the recent rise of measles cases in the United States

  2024cites this paper
• Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy.

  2024cites this paper
• The Increasing Occurrence of Infectious Diseases in Childhood: Is It Linked with Declining Vaccination Rates Across Society?

  2024cites this paper
• Unveiling immunity gaps and determining a suitable age for a third dose of the measles-containing vaccine: a strategic approach to accelerating measles elimination

  2024cites this paper
• Seroprevalence of measles antibody among immigrants in Gwangju, South Korea

  2024cites this paper
• Measles Infection Dose Responses: Insights from Mathematical Modeling

  2024cites this paper
• Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5-6 years.

  2024cites this paper
• Measles and Rubella Diagnostic and Classification Challenges in Near- and Post-Elimination Countries

  2024cites this paper
• Implications of Measles Inclusion by Commercial Syndromic Polymerase Chain Reaction Panels — United States, May 2022–April 2023

  2024influential citation
• Live-Attenuated Vaccines in Pediatric Solid Organ Transplant

  2024cites this paper
• Questionable Immunity to Mumps among Healthcare Workers in Italy—A Cross-Sectional Serological Study

  2024cites this paper
• Congenital and Perinatal Viral Infections: Consequences for the Mother and Fetus

  2024cites this paper
• Clinical and immunological outcomes of HIV-exposed uninfected and HIV-unexposed uninfected children in the first 24 months of life in Western Kenya

  2024cites this paper
• Measles — United States, January 1, 2020–March 28, 2024

  2024cites this paper
• Epidemiology of measles in southern Iran: trends, challenges, and vaccination insights

  2024cites this paper
• How Does Trauma Make You Sick? The Role of Attachment in Explaining Somatic Symptoms of Survivors of Childhood Trauma

  2024cites this paper
• Temporal and spatial analysis of over 7,000 measles cases outbreak from 2018 to 2019 in the Brazilian Amazon

  2024cites this paper
• High diagnostic accuracy of quantitative SARS-CoV-2 spike-binding-IgG assay and correlation with in vitro viral neutralizing activity

  2024cites this paper
• Vaccine-preventable diseases: Immune response in a large population of healthcare students.

  2024cites this paper
• Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020

  2024cites this paper
• Measles Foci Reduction Neutralization Test (FRNT).

  2024cites this paper
• Postpartum Measles, Varicella, and Rubella Vaccination Rates in Serologically Non-Immune Mothers with Public Insurance at an Urban Tertiary Care Center

  2024cites this paper
• Long-term Neutralizing Antibody Levels Against Measles and Rubella Viruses Among Adults With 3 Doses of Measles-Mumps-Rubella Vaccine

  2024influential citation
• Safety of Immunization for Children with Immune Thrombocytopenia

  2024cites this paper
• Recommended Adult Immunization Schedule, United States, 2024*

  2024cites this paper
• Measles Outbreak Associated with a Migrant Shelter — Chicago, Illinois, February–May 2024

  2024cites this paper
• Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice.

  2024cites this paper
• Transplacental Antibodies: Role of Maternal Vaccines and Immunity.

  2024cites this paper
• Clinical and Immunological Outcomes of HIV-Exposed Uninfected and HIV-Unexposed Uninfected Children in the First 24 Months of Life in Western Kenya

  2023cites this paper
• Serological Evaluation for Measles among Italian and Foreign Medical Students in a University Hospital in Rome

  2023cites this paper
• Measles virus transmission patterns and public health responses during Operation Allies Welcome: a descriptive epidemiological study

  2023cites this paper
• Immune globulin

  2023cites this paper
• Mapping the timeliness of routine childhood vaccination in The Gambia: A spatial modelling study.

  2023cites this paper
• Mumps vaccine effectiveness of a 3rd dose of measles, mumps, rubella vaccine in school settings during a mumps outbreak -- Arkansas, 2016-2017

  2023cites this paper
• The key 1000 life-changing days

  2023cites this paper
• The protective role of maternal genetic immunization on maternal‐fetal health and welfare

  2023cites this paper
• A Study Prevalence of Congenital Rubella Syndrome Cases Before and After Rubella Vaccination Campaign

  2023cites this paper